Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Delta-like ligand 3 (DLL3)
- Target
- DLL3
- Molecular classification
- Notch ligand
01
Overview
Delta-like ligand 3 (DLL3) is a Notch ligand involved in Notch signaling. Unlike other Notch ligands, DLL3 primarily acts as an inhibitor of Notch signaling. It is a therapeutic target in cancers with high DLL3 expression, particularly small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NENs).
02
Mechanism of action
DLL3 inhibition
03
Biological functions
Notch signalingCell differentiationCell proliferationCell survivalApoptosisSomitogenesis
04
Disease associations
CancerNeuroendocrine tumorigenesisJarcho-Levin syndrome
05
Safety considerations
Potential toxicities associated with targeted therapiesResistance to targeted therapies
06
Interacting drugs
Rovalpituzumab tesirine
07
Biomarkers
DLL3 expression level
Beyond the preview
Go deeper on Delta-like ligand 3 (DLL3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delta-like ligand 3 (DLL3).